[1] |
Wilding, J.; Bailey, C.; Rigney, U.; Blak, B.; Beekman, W.; Emmas, C. Glycated hemoglobin, body weight and blood pressure in type 2 diabetes patients initiating dapagliflozin treatment in primary care: a retrospective study. Diabetes Ther. 2016, 7, 695–711.
|
[2] |
Wang, Y.; Sheng, S.X. Study on the protective mechanism of cardiovascular and renal function of Dagliflozin in type 2 diabetic patients. Chin. J. Prim. Med. Pharm. 2021, 28, 504–509.
|
[3] |
Yang, Y. Effect of Dagliflozin on biochemical parameters, electrolytes and uric acid in type 2 diabetic patients. Chin. Foreign Med. Res. 2021, 19, 151–153.
|
[4] |
Hallow, K.M.; Helmlinger, G.; Greasley, P.J.; McMurray, J.J.V.; Boulton, D.W. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes. Metab. 2018, 20, 479–487.
|
[5] |
Liang, Z.S.; Xu, Z.M.; Ji, Q.W. Advances in evidence-based research on sodium-glucose cotransport protein 2 inhibitors in the treatment of heart failure and mechanisms. Chin. J. New Clin. Med. 2021, 14, 554–558.
|
[6] |
McMurray, J.J.V.; Wheeler, D.C.; Stefánsson, B.V.; Jongs, N.; Postmus, D.; Correa-Rotter, R.; Chertow, G.M.; Hou, F.F.; Rossing, P.; Sjöström, C.D.; Solomon, S.D.; Toto, R.D.; Langkilde, A.M.; Heerspink, H.J.L.;. Effects of dapagliflozin in patients with kidney disease, with and without heart failure. JACC Heart Fail. 2021, 9, 807–820.
|
[7] |
Liu, M.; Zhang, Y.M.; Feng, X.R.; Zheng, Q.; Wang, Y.C.; Liu, M.L. Short-term effects of dagliflozin on urine volume and blood and urine electrolytes in type 2 diabetic patients. Chin. J. Clin. Pharm. 2021, 37, 2569–2572.
|
[8] |
Lambers Heerspink, H.J.; de Zeeuw, D.; Wie, L.; Leslie, B.; List, J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 2013, 15, 853–862.
|
[9] |
Sha, S.; Polidori, D.; Heise, T.; Natarajan, J.; Farrell, K.; Wang, S.S.; Sica, D.; Rothenberg, P.; Plum-Mörschel, L. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2014, 16, 1087–1095.
|
[10] |
Dekkers, C.C.J.; Sjöström, C.D.; Greasley, P.J.; Cain, V.; Boulton, D.W.; Heerspink, H.J.L. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes. Metab. 2019, 21, 2667–2673.
|